Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Citius Oncology Inc.

    NASDAQ: CTOR · Real-Time Price · USD
    1.39
    -0.08 (-5.44%)
    At close: Jun 16, 2025, 3:59 PM
    1.37
    -1.44%
    Pre-market: Jun 17, 2025, 04:40 AM EDT

    Citius Oncology Statistics

    Share Statistics

    Citius Oncology has - shares outstanding. The number of shares has increased by null% in one year.

    Shares Outstanding

    n/a
    		 n/a

    Shares Change (YoY)

    n/a
    		 n/a

    Shares Change (QoQ)

    n/a
    		 n/a

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 5,150

    FTD / Avg. Volume

    n/a
    		 0.34%

    Short Selling Information

    The latest short interest is 25.5K, so 0.04% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 25.5K

    Short % of Shares Out

    n/a
    		 0.04%

    Short % of Float

    n/a
    		 0.46%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -4.7 and the forward PE ratio is 29.77. Citius Oncology's PEG ratio is 0.06.

    PE Ratio

    n/a
    		 -4.7

    Forward PE

    n/a
    		 29.77

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.6

    PB Ratio

    n/a
    		 2.16

    P/FCF Ratio

    n/a
    		 -20.41

    PEG Ratio

    n/a
    		 0.06
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Citius Oncology.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.34, with a Debt / Equity ratio of 0.08.

    Current Ratio

    n/a
    		 0.34

    Quick Ratio

    n/a
    		 0.08

    Debt / Equity

    n/a
    		 0.08

    Debt / EBITDA

    n/a
    		 -0.18

    Debt / FCF

    n/a
    		 -0.78

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 n/a

    Employee Count

    n/a
    		 undefined

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 576K

    Effective Tax Rate

    n/a
    		 -2.8%

    Stock Price Statistics

    The stock price has increased by null% in the last 52 weeks. The beta is -0.06, so Citius Oncology's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.06

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 0.88

    200-Day Moving Average

    n/a
    		 1.1

    Relative Strength Index (RSI)

    n/a
    		 76.99

    Average Volume (20 Days)

    n/a
    		 1,496,528

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -20.57M

    Net Income

    n/a
    		 -21.15M

    EBITDA

    n/a
    		 -20.57M

    EBIT

    n/a
    		 -20.57M

    Earnings Per Share (EPS)

    n/a
    		 -0.3
    Full Income Statement

    Balance Sheet

    The company has 112 in cash and 3.8M in debt, giving a net cash position of -3.8M.

    Cash & Cash Equivalents

    n/a
    		 112

    Total Debt

    n/a
    		 3.8M

    Net Cash

    n/a
    		 -3.8M

    Retained Earnings

    n/a
    		 -39.28M

    Total Assets

    n/a
    		 90.48M

    Working Capital

    n/a
    		 -26.32M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 126.35K and capital expenditures -5M, giving a free cash flow of -4.87M.

    Operating Cash Flow

    n/a
    		 126.35K

    Capital Expenditures

    n/a
    		 -5M

    Free Cash Flow

    n/a
    		 -4.87M

    FCF Per Share

    n/a
    		 -0.07
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CTOR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CTOR is $6, which is 331.7% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 331.7%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.51

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist